

Financial news for MDCO dated on 2020-02-18: Q4 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios

Financial news for MDCO dated on 2020-01-06: Novartis Completes Tender Offer for All Outstanding Shares of The Medicines Company for \$85/Share

Financial news for MDCO dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for MDCO dated on 2020-01-02: The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

Financial news for MDCO dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for MDCO dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for MDCO dated on 2019-12-19: Stocks That Hit 52-Week Highs On Thursday

Financial news for MDCO dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for MDCO dated on 2019-12-10: Stocks That Hit 52-Week Highs On Tuesday

Financial news for MDCO dated on 2019-12-05: Novartis Tender Offer for The Medicines Company Commences

Financial news for MDCO dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for MDCO dated on 2019-11-26: Benzinga's Top Upgrades, Downgrades For November 26, 2019

Financial news for MDCO dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for MDCO dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-11-26: SVB Leerink Downgrades Medicines Co to Market Perform, Raises Price Target to \$85

Financial news for MDCO dated on 2019-11-26: Chardan Capital Downgrades Medicines Co to Neutral

Financial news for MDCO dated on 2019-11-25: PreMarket Prep Recap: Merger Monday, Tesla Two-Step, Street Fades Netflix Downgrade

Financial news for MDCO dated on 2019-11-25: Mid-Afternoon Market Update: Dow Rises 150 Points; Sorrento Therapeutics Shares Spike Higher

Financial news for MDCO dated on 2019-11-25: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for MDCO dated on 2019-11-25: Mid-Day Market Update: Medicines Company Jumps Following Acquisition News; CymaBay Therapeutics Shares Plunge

Financial news for MDCO dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for MDCO dated on 2019-11-25: Benzinga's Top Upgrades, Downgrades For November 25, 2019

Financial news for MDCO dated on 2019-11-25: 36 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for MDCO dated on 2019-11-25: Novartis Confirms Deal To Acquire Medicines Company For \$9.7B

Financial news for MDCO dated on 2019-11-25: The Medicines Co shares are trading higher after the company announced it will be acquired by Novartis AG for \$85 per share.

Financial news for MDCO dated on 2019-11-25: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for MDCO dated on 2019-11-25: Oppenheimer Downgrades Medicines Co to Perform, Raises Price Target to \$85

Financial news for MDCO dated on 2019-11-25: Baird Downgrades Medicines Co to Neutral, Lowers Price Target to \$85

Financial news for MDCO dated on 2019-11-24: Novartis Confirms Agreement to Acquire the Medicines Company for \$85/Share

Financial news for MDCO dated on 2019-11-23: Novartis Nears Deal to Buy Medicines Co. for \$85/Share; ~\$7B

Financial news for MDCO dated on 2019-11-20: Evercore ISI Group Downgrades Medicines Co to In-Line

Financial news for MDCO dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for MDCO dated on 2019-11-20: 77 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-11-19: Mid-Afternoon Market Update: Kohl's Falls On Downbeat Earnings; Myovant Sciences Shares Climb

Financial news for MDCO dated on 2019-11-19: Medicines Co Option Alert: Dec 20 \$75 Calls Sweep (2) near the Ask: 1900 @ \$3.9 vs 3801 OI; Ref=\$70.5

Financial news for MDCO dated on 2019-11-19: Medicines Co Option Alert: Jan 17 \$30 Puts at the Bid: 6150 @ \$0.201 vs 7124 OI; Ref=\$69.945

Financial news for MDCO dated on 2019-11-19: Mid-Day Market Update: Crude Oil Down 2.5%; Medicines Company Shares Jump

Financial news for MDCO dated on 2019-11-19: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MDCO dated on 2019-11-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for MDCO dated on 2019-11-19: Mid-Morning Market Update: Markets Mostly Lower; Home Depot Reports Downbeat Sales

Financial news for MDCO dated on 2019-11-19: Medicines Company Shares Soar On Rumored Buyout Interest From Novartis

Financial news for MDCO dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for MDCO dated on 2019-11-19: 8 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for MDCO dated on 2019-11-19: The Medicines Co shares are trading higher following reports Novartis is considering making an offer to acquire the company.

Financial news for MDCO dated on 2019-11-19: 28 Stocks Moving in Tuesday's Pre-Market Session

Financial news for MDCO dated on 2019-11-19: Novartis Declines Comment on Media Report That It is Considering Offer for The Medicines Co

Financial news for MDCO dated on 2019-11-19: 72 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-11-18: Medicines Co Option Alert: Jan 17 \$75 Calls at the Ask: 3000 @ \$2.0 vs 13357 OI; Ref=\$57.11

Financial news for MDCO dated on 2019-11-18: The Medicines Co shares are trading higher after the company reported positive inclisiran data from a Phase 3 trial.

Financial news for MDCO dated on 2019-11-18: 5 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for MDCO dated on 2019-11-17: The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

Financial news for MDCO dated on 2019-11-16: The Medicines Company Announces ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing at AHA Scientific Sessions

Financial news for MDCO dated on 2019-11-10: The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

Financial news for MDCO dated on 2019-10-31: The Medicines Company shares trading lower as company's 10-Q filing, according to a Jefferies analyst, included new "going concern" language which introduces added risk.

Financial news for MDCO dated on 2019-10-31: Medicines Co. Shares Fall Over Last Few Mins. With Broader Market; Hearing Jefferies Highlighting Co. 10-Q Provides New Going Concern Language Which Introduces An Added Risk

Financial news for MDCO dated on 2019-10-30: The Medicines Co shares are trading lower after the company reported Q3 EPS was down from the same quarter last year.

Financial news for MDCO dated on 2019-10-30: Medicines Co Q3 Adj. EPS \$(0.72) Down From \$(0.7) YoY

Financial news for MDCO dated on 2019-10-23: Medicines Co Option Alert: Mar 20 \$65 Calls at the Ask: 1300 @ \$7.401 vs 2530 OI; Earnings 11/7 Before Open [est] Ref=\$57.695

Financial news for MDCO dated on 2019-10-22: The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug

Financial news for MDCO dated on 2019-10-21: Stocks That Hit 52-Week Highs On Monday

Financial news for MDCO dated on 2019-10-18: The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe

Financial news for MDCO dated on 2019-10-17: Stocks That Hit 52-Week Highs On Thursday

Financial news for MDCO dated on 2019-10-17: The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO

Financial news for MDCO dated on 2019-10-16: The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

Financial news for MDCO dated on 2019-10-11: Stocks That Hit 52-Week Highs On Friday

Financial news for MDCO dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for MDCO dated on 2019-10-10: Benzinga's Top Upgrades, Downgrades For October 10, 2019

Financial news for MDCO dated on 2019-10-10: 10 Biggest Price Target Changes For Thursday

Financial news for MDCO dated on 2019-10-10: Jefferies Downgrades Medicines Co to Hold, Raises Price Target to \$50

Financial news for MDCO dated on 2019-10-02: UPDATE: B. Riley FBR Maintains Outperform On The Medicines Co., Raises Target To \$95 To Reflect Firm's 'heightened conviction in inclisiran taking a dominant market share in the anti-PCSK9 marketplace following strong ORION-11/10/9 Ph. III results'

Financial news for MDCO dated on 2019-10-02: B. Riley Maintains Buy on Medicines Co, Raises Price Target to \$95

Financial news for MDCO dated on 2019-09-26: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

Financial news for MDCO dated on 2019-09-26: 55 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-09-25: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MDCO dated on 2019-09-25: Stocks That Hit 52-Week Highs On Wednesday

Financial news for MDCO dated on 2019-09-25: The Medicines Co shares are trading higher after the company's ORION-9 Phase 3 study of Inclisiran met its primary and all secondary endpoints.

Financial news for MDCO dated on 2019-09-25: A Peek Into The Markets: US Stock Futures Down; Crude Oil Falls Over 1%

Financial news for MDCO dated on 2019-09-25: The Medicines Co Announces ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients Met Primary And All Secondary Efficacy Endpoints

Financial news for MDCO dated on 2019-09-23: Stocks That Hit 52-Week Highs On Monday

Financial news for MDCO dated on 2019-09-17: Benzinga's Top Upgrades, Downgrades For September 17, 2019

Financial news for MDCO dated on 2019-09-17: The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study

Financial news for MDCO dated on 2019-09-17: Citigroup Downgrades Medicines Co to Neutral

Financial news for MDCO dated on 2019-09-16: Stocks That Hit 52-Week Highs On Monday

Financial news for MDCO dated on 2019-09-13: The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

Financial news for MDCO dated on 2019-09-09: Medicines Co Option Alert: Sep 20 \$55 Calls Sweep (33) near the Ask: 612 @ \$0.551 vs 1601 OI; Earnings 11/7 Before Open [est] Ref=\$46.74

Financial news for MDCO dated on 2019-09-06: Stocks That Hit 52-Week Highs On Friday

Financial news for MDCO dated on 2019-09-04: The Medicines Co. Shares Spike Above \$46 Technical Level, Up 2.6% Over Last Few Mins.; Not Seeing News To Justify Move Higher

Financial news for MDCO dated on 2019-09-04: Medicines Co Option Alert: Jan 17 \$55 Calls at the Ask: 5000 @ \$3.8 vs 4142 OI; Ref=\$46.41

Financial news for MDCO dated on 2019-09-04: A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019

Financial news for MDCO dated on 2019-09-04: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., September 04, 2019

Financial news for MDCO dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for MDCO dated on 2019-09-04: 66 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-09-03: Baird Reiterates Outperform, \$100 Target On Medicines Co. As Firm Notes Inclisiran 'findings, while early, give us incremental optimism for the ongoing CV outcomes trial (CVOT) ORION-4, to demonstrate CV benefit with inclisiran'

Financial news for MDCO dated on 2019-09-03: UPDATE: Oppenheimer On Medicines Co. Also Views Co. As 'an attractive potential M&A target, noting the company is currently undervalued at 3.8x EV/5-yr cons. sales est. vs. industry targets at 4.4x on average in 2019 YTD'

Financial news for MDCO dated on 2019-09-03: UPDATE: Oppenheimer Maintains Outperform On Medicines Co., Raises Target To \$60 As Firm Notes Positive Inclisiran Data 'significantly de-risk ORION-9&10 data to read-out sequentially in late 3Q'

Financial news for MDCO dated on 2019-09-03: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MDCO dated on 2019-09-03: Medicines Company Shares Reach 2-Year High Amid Positive Inclisiran Data

Financial news for MDCO dated on 2019-09-03: Medicines Co Option Alert: Jan 17 \$55 Calls at the Ask: 550 @ \$2.9 vs 3139 OI; Ref=\$44.14

Financial news for MDCO dated on 2019-09-03: 10 Biggest Price Target Changes For Tuesday

Financial news for MDCO dated on 2019-09-03: 32 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for MDCO dated on 2019-09-03: Citi Maintains Buy on Medicines Co, Raises Price Target to \$55

Financial news for MDCO dated on 2019-09-03: 26 Stocks Moving in Tuesday's Pre-Market

## Session

Financial news for MDCO dated on 2019-09-03: Oppenheimer Maintains Outperform on Medicines Co, Raises Price Target to \$60

Financial news for MDCO dated on 2019-09-03: Citigroup Maintains Buy on Medicines Co, Raises Price Target to \$55

Financial news for MDCO dated on 2019-09-03: A Peek Into The Markets: US Stock Futures Down; Dow Futures Tumble Over 200 Points

Financial news for MDCO dated on 2019-09-03: The Medicines Company shares are trading higher after the company presented results from its ORION-11 trial at ESC Congress 2019. In the trial, inclisiran met all primary and secondary efficacy endpoints.

Financial news for MDCO dated on 2019-09-03: Medicines Company Shares Rise 22% Premarket on Positive Inclisiran Data

Financial news for MDCO dated on 2019-09-02: The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight

Financial news for MDCO dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for MDCO dated on 2019-08-28: 64 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-08-27: 46 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MDCO dated on 2019-08-27: A Look At Benzinga Pro's Most-Searchd Tickers For August 27, 2019

Financial news for MDCO dated on 2019-08-27: The Medicines Company shares are trading higher on continued momentum after the company's phase 3 trial of Inclisiran met all primary and secondary efficacy endpoints.

Financial news for MDCO dated on 2019-08-27: Stocks That Hit 52-Week Highs On Tuesday

Financial news for MDCO dated on 2019-08-27: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning of Tuesday., August 27, 2019

Financial news for MDCO dated on 2019-08-27: 50 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-08-26: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for MDCO dated on 2019-08-26: A Look At Benzinga Pro's Most-Searchd Tickers For August 26, 2019

Financial news for MDCO dated on 2019-08-26: Good News For Bad Cholesterol Drug Sends Medicines Company Shares Flying

Financial news for MDCO dated on 2019-08-26: Medicines Co Option Alert: Jan 17 \$40 Calls Sweep (10) near the Ask: 500 @ \$5.8 vs 27217 OI; Ref=\$35.76

Financial news for MDCO dated on 2019-08-26: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning of Monday., August 26, 2019

Financial news for MDCO dated on 2019-08-26: 16 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for MDCO dated on 2019-08-26: The Medicines Company shares are trading higher after the company's phase 3 trial of Inclisiran met all primary and secondary efficacy endpoints.

Financial news for MDCO dated on 2019-08-26: 26 Stocks Moving in Monday's Pre-Market Session

Financial news for MDCO dated on 2019-08-26: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for MDCO dated on 2019-08-26: The Medicines Company Phase 3 Trial of Inclisiran Met all Primary and Secondary Efficacy Endpoints

Financial news for MDCO dated on 2019-08-20: Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Financial news for MDCO dated on 2019-07-25: David Einhorn's Q2 Letter To Greenlight Investors Shows New Stakes In Dillards, Chemours, Scientific Games

Financial news for MDCO dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for MDCO dated on 2019-07-24: Medicines Co Q2 EPS \$(0.63) Beats \$(0.73) Estimate

Financial news for MDCO dated on 2019-07-20: The Week Ahead In Biotech: Pharma Earnings Pick Up Pace

Financial news for MDCO dated on 2019-07-11: Mizuho Comments On News Praluent Will Be Pulled From Germany, Sees Positive Implications For Amgen's Repatha, The Medicine Co.'s Inclisiran

Financial news for MDCO dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for MDCO dated on 2019-06-30: Notable Insider Buys This Past Week: AbbVie, MGM and More

Financial news for MDCO dated on 2019-06-26: The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

Financial news for MDCO dated on 2019-06-26: 51 Biggest Movers From Yesterday

Financial news for MDCO dated on 2019-06-26: The Medicines Company Announces Prices 4.5M Share Public Offering of Common Stock @\$33/Share

Financial news for MDCO dated on 2019-06-25: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MDCO dated on 2019-06-25: The Medicines Co shares are trading lower after the company announced a \$150 million common stock offering.

Financial news for MDCO dated on 2019-06-25: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MDCO dated on 2019-06-25: The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

Financial news for MDCO dated on 2019-06-25: A Peek Into The Markets: US Stock Futures Down Ahead Of Economic Data

Financial news for MDCO dated on 2019-06-25: 7 Stocks To Watch For June 25, 2019

Financial news for MDCO dated on 2019-06-24: The Medicines Company Reports \$150M Common Stock Offering

Financial news for MDCO dated on 2019-06-04: These Bullish Medicines Company Options Trades Suggest More Upside Could Be Coming

Financial news for MDCO dated on 2019-06-03: Notable Insider Buys This Past Week: Coty, Zillow and More

Financial news for MDCO dated on 2019-05-26: Notable Insider Buys This Past Week: Bunge, Hain Celestial And More

Financial news for MDCO dated on 2019-05-20: Medicines Company Rallies On Positive LDL Cholesterol Study Results

Financial news for MDCO dated on 2019-05-20: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for MDCO dated on 2019-05-20: The Medicines Co shares are trading higher after interim results showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol by more than 50 percent.

Financial news for MDCO dated on 2019-05-18: Medicines Company New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years

Financial news for MDCO dated on 2019-05-11: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for MDCO dated on 2019-05-03: Medicines Co Option Alert: May 17 \$34

Calls Sweep (42) above Ask!: 610 @ \$0.948 vs 1758 OI; Ref=\$32.5099

Financial news for MDCO dated on 2019-04-29: Medicines Co Option Alert: May 17 \$34 Calls Sweep (40) near the Ask: 610 @ \$0.997 vs 1161 OI; Ref=\$32.35

Financial news for MDCO dated on 2019-04-26: The Medicines shares are trading higher after Goldman Sachs upgraded the company's stock from Neutral to Buy and raised the price target from \$25 to \$55.

Financial news for MDCO dated on 2019-04-26: Benzinga's Top Upgrades, Downgrades For April 26, 2019

Financial news for MDCO dated on 2019-04-26: Goldman Sachs Upgrades The Medicines Company - Common Stock to Buy, Raises Price Target to \$55

Financial news for MDCO dated on 2019-04-25: The Medicines Company Q1 EPS \$(0.62) Misses \$(0.58) Estimate

Financial news for MDCO dated on 2019-04-02: Medicines Co Option Alert: Apr 18 \$31 Calls Sweep (25) near the Ask: 500 @ \$0.75 vs 1093 OI; Earnings 4/24 Before Open [est] Ref=\$29.24

Financial news for MDCO dated on 2019-03-28: Benzinga's Top Upgrades, Downgrades For March 28, 2019

Financial news for MDCO dated on 2019-03-28: Baird Initiates Coverage On Medicines Co with Outperform Rating, Announces \$80 Price Target

Financial news for MDCO dated on 2019-03-21: Benzinga's Top Upgrades, Downgrades For March 21, 2019

Financial news for MDCO dated on 2019-03-21: Roth Capital Initiates Coverage On Medicines Co with Buy Rating, Announces \$75 Price Target

Financial news for MDCO dated on 2019-03-10: Insider Buys Of The Week: Arconic, CenturyLink, Hain Celestial and More

Financial news for MDCO dated on 2019-02-27: Medicines Co Q4 EPS \$(0.58) Beats \$(0.61) Estimate

Financial news for MDCO dated on 2019-01-07: The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials, Says No Material Safety Observations

Financial news for MDCO dated on 2018-12-27: Medicines Co CEO Timney Buys 2,926 @ Avg Price: \$17.90

Financial news for MDCO dated on 2018-12-23: Insider Buys Of The Week: Chesapeake Energy, Medicines Company, NuStar Energy

Financial news for MDCO dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for MDCO dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for MDCO dated on 2018-12-14: 51 Biggest Movers From Yesterday

Financial news for MDCO dated on 2018-12-13: Goldman Sachs Initiates Coverage On Medicines Co with Neutral Rating, Announces \$25 Price Target

Financial news for MDCO dated on 2018-12-13: 52 Biggest Movers From Yesterday

Financial news for MDCO dated on 2018-12-11: The Medicines Company Appoints Mark Timney As Chief Executive Officer

Financial news for MDCO dated on 2018-11-19: Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018

Financial news for MDCO dated on 2018-11-15: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018

Financial news for MDCO dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for MDCO dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for MDCO dated on 2018-11-08: The Medicines Company Q3 EPS \$(0.70)

Misses \$(0.55) Estimate, Sales \$(3.3M) Miss \$3.23M Estimate

Financial news for MDCO dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for MDCO dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for MDCO dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for MDCO dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for MDCO dated on 2018-10-01: The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded Data

Financial news for MDCO dated on 2018-08-24: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for MDCO dated on 2018-08-23: 24 Stocks Moving In Thursday's Pre-Market Session

Financial news for MDCO dated on 2018-08-01: The Medicines Company Q2 EPS \$(0.63) Misses \$(0.60) Estimate, Sales \$1.667M Miss \$7.31M Estimate

Financial news for MDCO dated on 2018-07-20: Medicines Co Option Alert: Aug 17 \$48 Calls at the Ask: 800 @ \$0.5 vs 0 OI; Earnings 8/8 Before Open [est] Ref=\$39.89

Financial news for MDCO dated on 2018-07-19: Delivering Alpha 2018: Everything You Need To Know

Financial news for MDCO dated on 2018-07-18: From Delivering Alpha Conference: Alex Denner Of Sarissa Capital Says Likes Ironwood Pharma, Medicines Co.

Financial news for MDCO dated on 2018-06-27: The Medicines Company Reports Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Review of Unblinded Data

Financial news for MDCO dated on 2018-06-26: The Medicines Company Announces New Data Presented At American Diabetes Association 78th Scientific Sessions Reinforce Potential Of Co.'s inclisiran In Patients With Diabetes

Financial news for MDCO dated on 2018-05-07: UPDATE: The Medicines Co. Says 'Phase III trials of inclisiran progressing as planned with no material safety observations'

Financial news for MDCO dated on 2018-05-07: UPDATE: The Medicines Co. Says 'Inclisiran drove sustained lowering of key atherogenic lipoproteins - non-HDL-C, ApoB, VLDL-C and Lp(a)'

Financial news for MDCO dated on 2018-05-07: The Medicines Co. Reports ORION-1 Phase II Data On Inclisiran, Showed 'reduced key atherogenic lipoproteins back to normal in 68% to 90% of patient studied'

Financial news for MDCO dated on 2018-04-25: Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Financial news for MDCO dated on 2018-04-25: The Medicines Company Q1 EPS \$(0.76) Beats \$(0.78) Est., Sales \$7.77M Misses \$7.99M Est.

Financial news for MDCO dated on 2018-04-20: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for MDCO dated on 2018-03-28: The Medicines Company Names Christopher Visioli as CFO, Replacing William B. O'Connor

Financial news for MDCO dated on 2018-03-07: Medicines Co Option Alert: Mar 16 \$35 Calls Sweep (2) at the Ask: 1688 @ \$1.0 vs 3986 OI; Earnings 4/25 Before Open [est] Ref=\$31.96

Financial news for MDCO dated on 2018-03-01: Medicines Co Option Alert: Mar 16 \$32 Puts Above Ask!: 1750 @ \$1.4 vs 5066 OI; Earnings 4/25 Before Open [est] Ref=\$33.13

Financial news for MDCO dated on 2018-03-01: Meg Tirrell Tweets: Breaking: Activist investor Alex Denner to gain board control at \$MDCO as company says it's shrinking board size to 7

Financial news for MDCO dated on 2018-02-21: The Medicines Company Reports Q4 EP



S\$(0.61) vs \$(1.28) Est., Sales \$8.6M vs \$17.4M In Prior Year Period

Financial news for MDCO dated on 2018-02-20: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule

Financial news for MDCO dated on 2018-02-19: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for MDCO dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for MDCO dated on 2018-01-30: Medicines Co Option Alert: Feb 16 \$33 Puts Sweep (32) at the Bid: 873 @ \$1.052 vs 0 OI; Earnings 4/25 Before Open [est] Ref=\$34.12

Financial news for MDCO dated on 2018-01-23: The Medicines Co. Shares Up ~\$0.90 Over Last Few Mins. Amid FDA Alert Highlighting Orphan Drug Designation For Inclisiran

Financial news for MDCO dated on 2018-01-23: Analyst/Investor Days Today For The Medicines Company, United Continental

Financial news for MDCO dated on 2018-01-23: 38 Biggest Movers From Yesterday

Financial news for MDCO dated on 2018-01-22: The Week Ahead: IPOs, Earnings, And FDA Actions Provide Catalysts

Financial news for MDCO dated on 2018-01-22: Citi Downgrades Esperion As Hope Of Acquisition Dwindles

Financial news for MDCO dated on 2017-12-22: Mid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge

Financial news for MDCO dated on 2017-12-01: Medicines Company To Sell Infectious Disease Unit To Melinta

Financial news for MDCO dated on 2017-11-30: Oppenheimer Raises Its Prognosis For The Medicines Company

Financial news for MDCO dated on 2017-11-30: Benzinga's Top Upgrades, Downgrades For November 30, 2017

Financial news for MDCO dated on 2017-11-30: Oppenheimer Upgrades The Medicines to Outperform

Financial news for MDCO dated on 2017-11-30: Wall Street's M&A Chatter From November 29: Nokia-Juniper, Tyler Technologies-Radio 10-33, Medicines Co-Melinta Therapeutics

Financial news for MDCO dated on 2017-11-30: Medicines Co Director Denner Buys 170,000 @ Avg Price: \$30.03 -Form 4

Financial news for MDCO dated on 2017-11-29: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MDCO dated on 2017-11-29: 35 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MDCO dated on 2017-11-29: Melinta Therapeutics to Resume Trading at 7:30 AM ET

Financial news for MDCO dated on 2017-11-29: The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics for \$270M; \$215M Cash and \$55M Stock

Financial news for MDCO dated on 2017-11-15: The Medicines Co. Names Fred Eshelman Chair

Financial news for MDCO dated on 2017-11-06: The Medicines Co., Alnylam Report Patient Dosing For Inclisiran Has Commenced

Financial news for MDCO dated on 2017-11-06: The Medicines Co., Alnylam Pharma Report Initiation Of Phase III Trials Of Inclisiran

Financial news for MDCO dated on 2017-10-26: Oppenheimer Out With A Note On Medicines Company, Says It's Increasingly Clear That A Deal For ID Business Is Progressing

Financial news for MDCO dated on 2017-10-25: 31 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MDCO dated on 2017-10-24: Guggenheim Initiates Coverage On The Medicines with Buy Rating, Announces \$45.00 Price Target

Financial news for MDCO dated on 2017-10-05: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for MDCO dated on 2017-10-05: UPDATE: The Medicines Co. Says 'VABOMERE was also associated with better safety and significantly better overall risk-benefit than best available therapy'

Financial news for MDCO dated on 2017-10-05: The Medicines Co. To Present New Data From TANGO II Study Of VABOMERE At IDWeek: 'VABOMERE was associated with higher overall cure and lower mortality versus "best available therapy" in subjects with known or suspected CRE'

Financial news for MDCO dated on 2017-08-30: Medicines Company Gets FDA Approval, Has 119% Upside According To This Analyst

Financial news for MDCO dated on 2017-08-30: 12 Biggest Mid-Day Losers For Wednesday

Financial news for MDCO dated on 2017-08-30: The Medicines Company Surrenders Early Gains After FDA Approval Of Vabomere

Financial news for MDCO dated on 2017-08-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MDCO dated on 2017-08-30: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of ADP, GDP Data

Financial news for MDCO dated on 2017-08-30: The Medicines Co. Reports FDA Approval Of VABOMERE For Treatment Of Adult Patients With Complicated UTI Including Pyelonephritis

Financial news for MDCO dated on 2017-08-30: Medicines Co Shares +6.2% Premarket Following FDA Approval of Urinary Tract Infection Drug Vabomere

Financial news for MDCO dated on 2017-08-29: Medicines Company PDUFA Date For Meropenem-vaborbacam Today

Financial news for MDCO dated on 2017-08-28: The Medicines Company and Alnylam Pharma Announces 'Positive' Data from the ORION-1 Phase II Trial

Financial news for MDCO dated on 2017-07-25: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MDCO dated on 2017-07-25: The Medicines Company Reports TANGO-2 Stopped Early For Superior Benefit-Risk Compared To Best Available Therapy For CRE By Data Safety And Monitoring Board

Financial news for MDCO dated on 2017-06-06: Dr. Reddy's Laboratories Launches Bivalirudin for Injection in U.S. Market

Financial news for MDCO dated on 2017-05-31: Mid-Afternoon Market Update: Vera Bradley Surges On Narrower-Than-Expected Loss; EnerSys Shares Slide

Financial news for MDCO dated on 2017-05-22: Oppenheimer Initiates Coverage On The Medicines with Perform Rating, Announces \$50.00 Price Target

Financial news for MDCO dated on 2017-05-16: Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics

Financial news for MDCO dated on 2017-04-26: UPDATE: The Medicines Co., Alnylam Says NDA Submission for Inclisiran Expected At or Around End of '19

Financial news for MDCO dated on 2017-04-26: UPDATE: The Medicines Co., Alnylam Said Primary Endpoint for All of Inclisiran's Pivotal Trials Will be LDL-C Change from Baseline

Financial news for MDCO dated on 2017-04-26: The Medicines Co., Alnylam Earlier Announced Deal with FDA on Phase III Trial for Inclisiran

Financial news for MDCO dated on 2017-04-26: The Medicines Company Q1 EPS \$(1.05) vs \$(1.24) Est, Sales \$24.2M vs \$34.1M Est

Financial news for MDCO dated on 2017-04-11: Benzinga's Option Alert Recap From April 11

Financial news for MDCO dated on 2017-04-11: Option Alert: Medicines Co May 75.0 Calls Sweep: 500 @ ASK \$2.05: 500 traded vs 114 OI: Earnings 5/8 Before Open [est] \$54.82 Ref

Financial news for MDCO dated on 2017-04-07: Benzinga's Option Alert Recap From April 7

Financial news for MDCO dated on 2017-04-07: Option Alert: Medicines Co May 65.0 Calls Sweep: 1000 @ ASK \$2.05: 1000 traded vs 1592 OI: Earnings 5/8 Before Open [est] \$50.66 Ref

Financial news for MDCO dated on 2017-04-06: Hearing Federal Appeals Court Has Ruled Mylan Can Proceed with Generic Version of Angiomax by Medicines Co.

Financial news for MDCO dated on 2017-03-23: Option Alert: Medicines Co Apr 60.0 Calls Sweep: 1014 @ ASK \$1.096: 1019 traded vs 3444 OI: Earnings 5/8 Before Open (est) \$50.00 Ref

Financial news for MDCO dated on 2017-03-17: 20 Biggest Mid-Day Losers For Friday

Financial news for MDCO dated on 2017-03-17: UPDATE: Medicines Co., Alnylam Announce 'actively preparing to advance inclisiran into comprehensive, global Phase III development - initially focused on United States and Europe'

Financial news for MDCO dated on 2017-03-17: UPDATE: The Medicines Co., Alnylam Announce 'Inclisiran demonstrated significant and sustained reductions in LDL-C and high standards of safety and tolerability'

Financial news for MDCO dated on 2017-03-17: The Medicines Co., Alnylam Report Final Results from ORION-1 Phase 2 Study of Inclisiran

Financial news for MDCO dated on 2017-03-17: Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher

Financial news for MDCO dated on 2017-03-17: The Medicines Co. Shares Down 20%; Hearing Leerink Has Issued Defensive Comments on Name

Financial news for MDCO dated on 2017-03-17: Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates

Financial news for MDCO dated on 2017-02-28: The Medicines Company Q4 EPS \$(1.19) vs \$(1.43) Est, Sales \$25.2M vs \$26.9M Est

Financial news for MDCO dated on 2017-02-21: The Medicines Company Files NDA for Carbavance

Financial news for MDCO dated on 2017-02-03: Benzinga's Option Alert Recap From February 3

Financial news for MDCO dated on 2017-02-03: 18 Biggest Mid-Day Gainers For Friday

Financial news for MDCO dated on 2017-02-03: Option Alert: Medicines Co Apr 32 Put; 2000 @Bid @\$1.90

Financial news for MDCO dated on 2017-02-03: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for MDCO dated on 2017-02-02: Esperion, Medicines Company Shares Higher After-Hours; Amgen Said Repatha Reduces Risk of Cardiovascular Events

Financial news for MDCO dated on 2017-01-08: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran

Financial news for MDCO dated on 2017-01-06: The Medicines Company Is A Top Pick For 2017

Financial news for MDCO dated on 2017-01-06: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for MDCO dated on 2016-12-09: MEDICINES CO /DE: Cox Christopher T (EVP & Chief Corp. Dev. Officer) Buys 105,500 @ Avg Price: \$33.20

Financial news for MDCO dated on 2016-12-05: The Medicines Company Is A Major Cardiovascular Player In The Making

Financial news for MDCO dated on 2016-12-05: Benzinga's Top Initiations

Financial news for MDCO dated on 2016-12-05: The Market In 5 Minutes: Gold's New Market, Dakota Pipeline And A Nike Upgrade

Financial news for MDCO dated on 2016-12-05: H.C. Wainwright Initiates Coverage On The Medicines at Buy, Announces \$57.00 Target

Financial news for MDCO dated on 2016-11-15: Alnylam, Medicines Co. Shares Initially Spike Sharply Higher Following ORION-1 Study of Inclisiran; Both Stocks Have Now Sold Off Sharply: Alnylam Down 4%, Medinices Down 6.5% for Session

Financial news for MDCO dated on 2016-11-15: UPDATE: Medicines Co. Plans to Advance Inclisiran Aggressively in Global Phase 3 Development Program

Financial news for MDCO dated on 2016-11-15: UPDATE: The Medicines Co., Alnylam Say ORION-1 Study Showed Significant LDL-C Reductions Sustained Out to 180 Days Following Single Dose

Financial news for MDCO dated on 2016-11-15: The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si), Study Meets All Interim Analysis Goals

Financial news for MDCO dated on 2016-11-15: The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si)

Financial news for MDCO dated on 2016-11-15: The Medicines Company Phase 2 180-Day Data On PCSKsi-ORION-1 Presented At AHA Scientific Sessions Today

Financial news for MDCO dated on 2016-11-13: Alnylam, The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran in NEJM

Financial news for MDCO dated on 2016-11-09: Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%

Financial news for MDCO dated on 2016-11-07: The Medicines Company Discontinues Development of MDCO-216 Due To Top-Line Efficacy Data Which Provided Insufficient Basis For Further Investment By Company

Financial news for MDCO dated on 2016-10-26: The Medicines Company Q3 EPS \$(0.64) vs \$(1.30) est, Revenue \$37.6M vs \$37.3M est

Financial news for MDCO dated on 2016-10-18: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for MDCO dated on 2016-10-18: 16 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MDCO dated on 2016-10-18: The Medicines Company Reports Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si; Continues To Show High Safety & Tolerability

Financial news for MDCO dated on 2016-10-10: Option Alert: MDCO Nov16 40.0 Calls Sweep: 1117 @ ASK \$3.477: 1256 traded vs 2079 OI: Earnings 11/1 \$36.77 Ref

Financial news for MDCO dated on 2016-10-06: 12 Biggest Mid-Day Losers For Thursday

Financial news for MDCO dated on 2016-10-06: Mid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter Shares Slide

Financial news for MDCO dated on 2016-10-06: Mid-Morning Market Update: Markets Open Lower; Yum! Brands Sales Miss Estimates

Financial news for MDCO dated on 2016-10-06: Jefferies Analyst Earlier Suggested Alnylam News Has 'No Read Through' for Medicines Co.

Financial news for MDCO dated on 2016-10-06: The Medicines Co. Shares Down 9% in Premarket Action Amid Alnylam News; Co. Said Review Found No Material Safety Issue, No Drug-Related Neuropathy Observed

Financial news for MDCO dated on 2016-10-06: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for MDCO dated on 2016-10-05: The Medicines Company Reports Interim Analysis To Be Presented At AHA Meeting Nov. 15th, Says No Material Safety Issue Has Been Observed

Financial news for MDCO dated on 2016-09-30: Chardan Rates Regeneron A Sell, Advises Caution

Financial news for MDCO dated on 2016-09-23: Option Alert: MDCO Nov. \$42 Calls Showing Volume ~3,000, Nov. \$50 Calls Showing Vol. ~6,000

Financial news for MDCO dated on 2016-09-23: 20 Stocks Which Rallied Three Days On Increasing Volume

Financial news for MDCO dated on 2016-09-21: The Medicines Company Awarded up to \$132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA

Financial news for MDCO dated on 2016-09-01: Watch These 7 Huge Put Purchases In Thursday Trade

Financial news for MDCO dated on 2016-08-31: Option Alert: The Medicines Co Apr 21 \$35 Puts at the bid: 500 @ 5.401 vs. Open Interest 0

Financial news for MDCO dated on 2016-08-31: Option Alert: The Medicines Co Apr 21 \$35 Puts at the bid: 500 @ 5.401 vs. Open Interest 0

Financial news for MDCO dated on 2016-08-30: 6 Stocks Moving After Hours: Medical Data, Earnings, Non-Timely Filings

Financial news for MDCO dated on 2016-08-30: The Medicines Company Reports MDCO-216 Upper Statistical Boundary For Efficacy Not Met, Which Permits Early Termination By Company; Summary Data Received By Company From IDM Committee Are Inconclusive; Recommends That MILANO-PILOT Study Continue

Financial news for MDCO dated on 2016-08-30: Medicines Co Shares Fall to \$37.00 After-Hours

Financial news for MDCO dated on 2016-08-23: Option Alert: MDCO Nov16 44.0 Calls Sweep: 500 @ ASK \$3.98: 500 traded vs 3007 OI: \$39.65 Ref

Financial news for MDCO dated on 2016-08-20: Friday's After-Hours Movers

Financial news for MDCO dated on 2016-08-02: Hearing Evercore ISI Analyst Suggesting Medicines Co. Overhang May Have Been Removed as Pfizer Exec on Earnings Call Disclosed Co.'s PCSK9 Being Shelved

Financial news for MDCO dated on 2016-07-27: The Medicines Company Q2 EPS (\$0.62) vs (\$1.16) est, Revenue \$54.7M vs \$41.9M est

Financial news for MDCO dated on 2016-07-20: Watch These 10 Huge Call Purchases In Wednesday Trade

Financial news for MDCO dated on 2016-07-19: Medicines Co Spikes Higher on Vol

Financial news for MDCO dated on 2016-07-19: Option Alert: MDCO Sep16 38.0 Calls Sweep: 800 @ ASK \$2.00: 800 traded vs 0 OI: Earnings 8/3 \$34.46 Ref

Financial news for MDCO dated on 2016-07-12: Federal Circuit Rules for The Medicines Company in Angiomax Patent Litigation

Financial news for MDCO dated on 2016-07-11: Hearing Medicines Co. Has Won Appeal Related to Angiomax Generic

Financial news for MDCO dated on 2016-07-11: Medicines Co Spikes to High of \$35.87 on Vol

Financial news for MDCO dated on 2016-06-27: The Medicines Company Announces Phase 3 TANGO 1 Clinical Trial of CARBAVANCE Met Primary Endpoints

Financial news for MDCO dated on 2016-06-14: The Medicines Company Initiates Phase II Study For Anesthetic

Financial news for MDCO dated on 2016-06-02: The Medicines Co. Reports Completion of Patient Enrollment for ORION-1 Study of PCSK9si

Financial news for MDCO dated on 2016-05-26: The Medicines Company Reports Completion of Patient Enrollment Ahead Of Schedule in Phase 3 TANGO 1 Study of CARBAVANCE for Treatment of Complicated Urinary Tract Infections

Financial news for MDCO dated on 2016-05-18: Medicines Co Vol Spike

Financial news for MDCO dated on 2016-05-16: The Medicines Co. Names Tony Kingsley COO

Financial news for MDCO dated on 2016-05-09: The Medicines Co. To Divest Non-Core

Cardiovascular Assets To Chiesi Farmaceutici S.p.A For \$792M

Financial news for MDCO dated on 2016-05-09: The Medicines Co. Reports Q1 EPS \$(1.03) vs. Est. \$(0.88), Rev. \$50.3M vs. Est. \$50.1M

Financial news for MDCO dated on 2016-05-05: Cowen & Company Initiates Coverage on The Medicines at Outperform

Financial news for MDCO dated on 2016-04-11: The Medicines Company Announces FDA Fast Track Designation for CARBAVANCE

Financial news for MDCO dated on 2016-03-21: Chardan Capital Maintains Buy on The Medicines, Removes \$65.00 PT

Financial news for MDCO dated on 2016-02-17: The Medicines Co. Reports Q4 Adj. EPS from Continuing Operations \$(0.88) vs \$(1.54) Est., Sales \$67.2M vs \$64M Est.

Financial news for MDCO dated on 2016-02-17: Earnings Scheduled For February 17, 2016

Financial news for MDCO dated on 2016-02-03: The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors

Financial news for MDCO dated on 2016-02-03: The Medicines Company Appoints Alexander J. Denner To Board

Financial news for MDCO dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for MDCO dated on 2016-01-26: John Paulson Puts Up Personal Holdings To Continue Longs In Greece, Puerto Rico & Mallinckrodt?

Financial news for MDCO dated on 2016-01-25: RBC Capital Calls The Medicines Co Undervalued, Calls Current Setup 'most attractive in stock's history'

Financial news for MDCO dated on 2016-01-22: JPMorgan Reiterates Overweight On Medicines Co, Sees \$50 Per Share On DCF Basis

Financial news for MDCO dated on 2016-01-20: Mid-Afternoon Market Update: Dow Falls Over 400 Points; Advanced Micro Devices Shares Drop After Disappointing Guidance

Financial news for MDCO dated on 2016-01-20: UPDATE: Reuters Report Suggests The Medicines Co. Has Been in Talks with Potential Buyers Related to Infectious Disease Care, Surgery, Perioperative Care Units

Financial news for MDCO dated on 2016-01-20: Hearing The Medicines Co. Has Said Bidders Are Focused on Asset Purchases

Financial news for MDCO dated on 2016-01-20: Shares Of Medicine Co. Falling

Financial news for MDCO dated on 2016-01-20: Medicines Co Up For Sale? Bloomberg, Reuters Info Comes Day After Benzinga Report; Companies Decline Comment

Financial news for MDCO dated on 2016-01-20: Spokesperson from The Medicines Co. Declines Comment Following Report of Takeover Interest

Financial news for MDCO dated on 2016-01-20: Benzinga's Volume Movers

Financial news for MDCO dated on 2016-01-20: The Medicines Co Seeking Sale -Bloomberg

Financial news for MDCO dated on 2016-01-20: The Medicines Company Spikes To \$36.03/Share, Now Trading At \$35.58/Share

Financial news for MDCO dated on 2016-01-19: Medicines Company Shares Make Odd Mid-Day Spike; Is The Company A Takeover Target?

Financial news for MDCO dated on 2016-01-19: The Medicines Co. Shares Spiking Higher Off Session Low Over Last Few Mins; Stock Now Up ~\$0.80 Over Last Four Mins

Financial news for MDCO dated on 2016-01-11: The Medicines Compnay Initiates Sites AND Begins Enrolling Patients In Dose-Finding Phase 2 Study For PCSK9 Synthesis Inhibitor For ASCVD

Financial news for MDCO dated on 2016-01-11: aTyr Reports Update For 2016 Company Outlook

Financial news for MDCO dated on 2016-01-08: 12 Biotechs With Binary Events Coming This Year

Financial news for MDCO dated on 2016-01-06: Jefferies' Best Biotech Ideas For 2016

(And Beyond)

Financial news for MDCO dated on 2015-12-23: 8-K from Medicines Co. Shows Deal to Sell Hemostasis Unit to Mallinckrodt for Upfront Payment ~\$175M, Potential Milestone Payments Up to \$235M

Financial news for MDCO dated on 2015-12-21: Chardan's Amusa Earlier Issued Late-Afternoon Intraday Note on The Medicines Co. Suggesting 'Clear buying opportunity after a 9% decline on incorrect anonymous post'

Financial news for MDCO dated on 2015-12-21: Option Alert: MDCO Apr16 33.0 Puts: 1226 @ ASK \$2.50: 2002 traded vs 25 OI: \$37.97 Ref

Financial news for MDCO dated on 2015-12-18: UPDATE: Mallinckrodt Sees New Products Potentially Adding Between \$40M-\$45M in Incremental Sales During FY16

Financial news for MDCO dated on 2015-12-18: UPDATE: Mallinckrodt Deal for RECOTHROM, PreveLeak Sealant, RAPLIXA with The Medicines Co.

Financial news for MDCO dated on 2015-12-18: Mallinckrodt Reports Diversification of Hospital Growth Portfolio: Will Invest in Market Development of RECOTHROM, RAPLIXA, PreveLeak, Make Upfront Payment of ~\$175M

Financial news for MDCO dated on 2015-12-14: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy

Financial news for MDCO dated on 2015-12-09: The Medicines Co. CFO Glenn Sblendorio To Retire, Names William O'Connor CFO

Financial news for MDCO dated on 2015-11-20: The Medicines Co. Reports Received EC Approval for IONSYS 40 mg/Dose

Financial news for MDCO dated on 2015-11-13: Federal Circuit Overturns Decision On Angiomax Patients, The Medicines Company Request For Rehearing of Appeal

Financial news for MDCO dated on 2015-11-13: Medicine's Company Angiomax Patent Invalidation Vacated by U.S. Court of Appeals for the Federal Circuit

Financial news for MDCO dated on 2015-11-13: Medicines Co Spikes Higher

Financial news for MDCO dated on 2015-11-04: Chardan: Time To Buy The Medicines Co.

Financial news for MDCO dated on 2015-11-04: Benzinga's Top Initiations

Financial news for MDCO dated on 2015-11-04: Chardan Sees Promise Of ALN-PCSSc, Initiates The Medicines Co. With Buy

Financial news for MDCO dated on 2015-11-04: Chardan Capital Initiates Coverage on The Medicines Company at Buy, Announces \$50.00 PT

Financial news for MDCO dated on 2015-10-06: The Medicines Co., SymBio Pharma Report Establishment of Strategic Partnership for IONSYS in Japan, Medicines Co. to Receive Upfront \$10M Payment

Financial news for MDCO dated on 2015-10-01: The Medicines Company Announces BARDA Exercises Next Option on Contract for Support of the Development of CARBAVANCE(r) (meropenem/RPX7009) for Drug-Resistant Gram-Negative Pathogens

Financial news for MDCO dated on 2015-09-01: Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing PCI via the Radial Approach

Financial news for MDCO dated on 2015-08-31: Mid-Afternoon Market Update: NASDAQ Down 1.3%; Medicines Company Shares Gain Following Announcement Of Positive ALN-PCSSc Study Results

Financial news for MDCO dated on 2015-08-31: Mid-Day Market Update: Crude Oil Surges 5.5%; ConforMIS Shares Tumble

Financial news for MDCO dated on 2015-08-31: Benzinga's Volume Movers

Financial news for MDCO dated on 2015-08-31: Stocks Hitting 52-Week Highs

Financial news for MDCO dated on 2015-08-31: Mid-Morning Market Update: Markets Open Lower; Carlyle Group To Acquire Blyth For \$6/Share

Financial news for MDCO dated on 2015-08-31: Morning Market Gainers

Financial news for MDCO dated on 2015-08-31: Benzinga's Top #PreMarket Gainers

Financial news for MDCO dated on 2015-08-31: Medicines Company +25% Premarket Following Announcement of Positive ALN-PCSSc Study Results

Financial news for MDCO dated on 2015-08-28: Benzinga's Top Upgrades

Financial news for MDCO dated on 2015-08-28: Jefferies Upgrades The Medicines Company to Buy, Raises PT to \$43.00

Financial news for MDCO dated on 2015-08-24: The Medicines Company Announces Participation at 2015 European Society of Cardiology Congress in London, Will Present Cardiovascular Product Portfolio Results

Financial news for MDCO dated on 2015-08-14: Volume And Volatility Alert: Medicines Company

Financial news for MDCO dated on 2015-07-29: Why Is The Medicines Company Stock Falling? This Analyst May Have An Answer

Financial news for MDCO dated on 2015-07-29: The Medicines Co. Reports Q2 EPS \$(0.71) vs. Est. \$(0.48), Rev. \$90.5M vs. Est. \$122.58M

Financial news for MDCO dated on 2015-07-09: 8-K from The Medicines Co. Shows Deal with Sandoz for Exclusive Rights to Sell in US Bivalirudin, Co. Will Supply Sandoz with Product

Financial news for MDCO dated on 2015-07-06: Mizuho Securities Upgrades The Medicines Company to Buy

Financial news for MDCO dated on 2015-07-02: The Medicines Co. Issues Release Announcing US Appeals Court Ruled Against Co. in Angiomax Patent Case with Hospira

Financial news for MDCO dated on 2015-06-25: Medicines Co Spikes Higher

Financial news for MDCO dated on 2015-06-23: RBC's Adnan Butt on The Medicines Co. Following Cangrelor Approval: 'Near- and Long-Term Catalysts Should Take Stock Higher,' Sees Upside Scenario Price Target \$66

Financial news for MDCO dated on 2015-06-22: Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says

Financial news for MDCO dated on 2015-06-22: The Medicines Company Announces FDA Approval of KENGREAL as an Adjunct to Percutaneous Coronary Intervention for Reducing Thrombotic Events

Financial news for MDCO dated on 2015-06-22: Adam Feuerstein Tweets: '\$MDCO FDA approves cangrelor. Brand name Kengreal.'

Financial news for MDCO dated on 2015-06-22: Shares of Medicines Co. Volatile, Slightly Lower Over Last Few Mins Following Reuters Headline Suggesting FDA Has Approved New Antiplatelet Drug

Financial news for MDCO dated on 2015-06-01: The Medicines Company Reports Results of Phase 1 Study for Novel Investigational Intravenous Anesthetic, ABP-700

Financial news for MDCO dated on 2015-05-29: Who's The Next Big Pharma Acquisition?

Financial news for MDCO dated on 2015-05-05: The Medicines Co. Reports Q2 GAAP EPS \$0.08, Sales \$126.5M vs \$139M Est.

Financial news for MDCO dated on 2015-04-30: From FDA Newsroom: 'FDA approves Raplixa to help control bleeding during surgery,' Watch Shares of Medicines Co.

Financial news for MDCO dated on 2015-04-20: FDA Approves New Formulation of MINOCIN (minocycline) for Injection

Financial news for MDCO dated on 2015-04-16: Citi Sees Limited Sales For Blood-Clot Drug At The Medicines Company

Financial news for MDCO dated on 2015-04-15: The Medical Company To Resume Trade At 5:45PM

Financial news for MDCO dated on 2015-04-15: UPDATE: The Medicines Co. Announces FDA Panel Voted 9-2 for Recommendation of Cangrelor Approval

Financial news for MDCO dated on 2015-04-15: FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor



Financial news for MDCO dated on 2015-04-15: Medicines Company Trading Halted

Financial news for MDCO dated on 2015-04-15: FDA Panel Votes 7-2 In Favor of Approval of Medicine Co's Cangrelor, In Certain Patients Undergoing Angioplasty Procedures -Reuters

Financial news for MDCO dated on 2015-04-15: The Medicines Co. Announces Shares Halted Today Ahead of FDA Advisory Committee to Review NDA for Cangrelor

Financial news for MDCO dated on 2015-04-15: The Medicines Co. Shares Halted News Pending

Financial news for MDCO dated on 2015-04-13: Hearing FDA Has Posted a Staff Review on The Medicines Co.'s Cangrelor, Says Should Be Approved

Financial news for MDCO dated on 2015-04-11: Mizuho Analyst On The Fence At Medicines Co. Pending Patent Appeal

Financial news for MDCO dated on 2015-04-10: Morning Market Losers

Financial news for MDCO dated on 2015-04-10: Benzinga's Top #PreMarket Losers

Financial news for MDCO dated on 2015-04-10: Medicines Co Shares Fall 8.5% Premarket on Weak Guidance

Financial news for MDCO dated on 2015-04-09: Extreme Networks, Citrix And AngioDynamics Lead Thursday's After-Hours Movers

Financial news for MDCO dated on 2015-04-09: Medicines Company Falls After Hours Following Company 8-K Shows Expected Drop In Q1 Revenues

Financial news for MDCO dated on 2015-04-09: Medicines Company Resumes Trading; Down 13%

Financial news for MDCO dated on 2015-04-09: PREVIEW: Medicines Company to Resume Trading at 4:30PM ET

Financial news for MDCO dated on 2015-04-01: The Medicines Company Settles Angiomax Patent Litigation With Sun

Financial news for MDCO dated on 2015-04-01: The Medicines Company Settles Angiomax Patent Litigation With Sun Pharmaceutical Industries

Financial news for MDCO dated on 2015-03-30: The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products

Financial news for MDCO dated on 2015-03-30: The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL(tm) (cangrelor), ORBACTIV(r) (oritavancin) and RAPLIXA

Financial news for MDCO dated on 2015-03-27: Citigroup Initiates Coverage on The Medicines Company at Neutral, Announces \$30.00 PT

Financial news for MDCO dated on 2015-03-19: Mizuho Securities Initiates Coverage on The Medicines Company at Neutral, Announces \$30.00 PT

Financial news for MDCO dated on 2015-03-09: The Medicines Company Falls 10% Following Angiomax Court Hearing

Financial news for MDCO dated on 2015-02-18: Medicines Company Q4 EPS \$0.20, Does not Compare to Estimate, Sales \$191M vs \$189.8M

Financial news for MDCO dated on 2015-02-18: Earnings Scheduled For February 18, 2015

Financial news for MDCO dated on 2015-02-04: The Medicines Company Acquires Annovation Biopharma; Terms Not Disclosed

Financial news for MDCO dated on 2015-01-23: EMA Recommends The Medicines Company's Cangrelor for Approval -Reuters

Financial news for MDCO dated on 2015-01-23: EMA Recommends The Medicines Company's Oritavancin for Approval -Reuters

Financial news for MDCO dated on 2015-01-22: Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs

Financial news for MDCO dated on 2015-01-21: Leerink Swann Upgrades Medicines Company To Outperform

Financial news for MDCO dated on 2015-01-21: Benzinga's Top Upgrades

Financial news for MDCO dated on 2015-01-21: Leerink Swann Upgrades The Medicines to Outperform, Raises PT to \$31.00

Financial news for MDCO dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for MDCO dated on 2015-01-07: What Investors Should Expect From Rockwell Medical's Next FDA Decision

Financial news for MDCO dated on 2015-01-07: Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops Estimates

Financial news for MDCO dated on 2015-01-07: Morning Market Losers

Financial news for MDCO dated on 2015-01-06: Tuesday's After-Hours Movers

Financial news for MDCO dated on 2015-01-06: 8-K from The Medicines Co. Shows Expecting FY14 Sales to be at Lower End of \$720.0M-735.0M Range

Financial news for MDCO dated on 2015-01-06: The Medicines Company Announces Intention to Offer \$300M of Convertible Notes

Financial news for MDCO dated on 2014-12-18: The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China

Financial news for MDCO dated on 2014-12-18: The Medicines Company, SciClone Pharmaceuticals Announce Strategic Partnership for Two Cardiovascular Products in China

Financial news for MDCO dated on 2014-12-11: Alnylam, The Medicines Company Announce Initiation Of Phase 1 Clinical Trial For ALN-PCSsc

Financial news for MDCO dated on 2014-12-11: Alnylam, The Medicines Co. Report Initiation of Phase 1 Trial for ALN-PCSsc, Earns \$10M Milestone from The Medicines Co.

Financial news for MDCO dated on 2014-11-20: The Medicines Company Surges Amid Credit Suisse Upgrade

Financial news for MDCO dated on 2014-11-20: Credit Suisse Upgrades The Medicines Company to Outperform, Raises PT to \$33.00

Financial news for MDCO dated on 2014-11-16: The Medicines Company Presents Positive Phase 1 Data for Investigational Agent MDCO-216

Financial news for MDCO dated on 2014-11-05: US Stock Futures Surge Ahead Of Earnings, ADP Data

Financial news for MDCO dated on 2014-11-05: The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE in Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria

Financial news for MDCO dated on 2014-11-05: Medicines Company Enrolls First Patient in Phase 3 Studies of CARBAVANCE for Treatment of Serious Bacterial Infections

Financial news for MDCO dated on 2014-10-29: Credit Suisse Maintains Neutral on The Medicines Company, Raises PT to \$27.00

Financial news for MDCO dated on 2014-10-28: Midday Gainers From October 28: Buffalo Wild Wings, Integrated Device Technology, Cliffs Natural Resources And More

Financial news for MDCO dated on 2014-10-28: The Medicines Company To Present Results Of Phase III Trial Of Investigational Hemostatic Agent RAPLIXA

Financial news for MDCO dated on 2014-10-28: Morning Market Movers

Financial news for MDCO dated on 2014-10-28: Credit Suisse Maintains Neutral on The Medicines Company, Raises PT to \$27.00

Financial news for MDCO dated on 2014-10-27: Medicines Company Announces Favorable Judgment in Angiomax Patent Litigation

Financial news for MDCO dated on 2014-10-27: Medicines Co. Has Won Patent Fight Against Mylan Related to Angiomax

Financial news for MDCO dated on 2014-10-22: From The Medicines Company Earnings

Conference Call: Sees FY2014 Sales \$720.0M-735.0M vs \$750.0M Est

Financial news for MDCO dated on 2014-10-22: Medicines Co. See Charges Of \$10M to \$14M In Q4; Cite Restructuring For Reason

Financial news for MDCO dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for MDCO dated on 2014-10-10: Credit Suisse Maintains Neutral on The Medicines Company, Lowers PT to \$26.00

Financial news for MDCO dated on 2014-10-09: BACTIVTM Phase 3 SOLO II Trial Results Published In The Journal Clinical Infectious Diseases

Financial news for MDCO dated on 2014-08-06: Medicines Company Announces FDA Approves ORBACTIV for Use in Acute Bacterial Skin and Skin Structure Infections

Financial news for MDCO dated on 2014-08-06: Shares of Medicines Co. Now Up ~\$1 as FDA Has Announced Approval of Orbactiv

Financial news for MDCO dated on 2014-07-23: The Medicines Company Reports Q2 EPS of \$(0.08) vs \$(0.02) Est; Revenue of \$183.80M vs \$183.75M Est

Financial news for MDCO dated on 2014-07-07: The Medicines Company Announces The European Medicines Agency Have Granted Authorization for Renewal For Angiox

Financial news for MDCO dated on 2014-06-10: Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

Financial news for MDCO dated on 2014-05-01: Medicines Co Says Data Show Alnylam's Conjugate Platform Demonstrated Robust, Durable and Clamped Knockdown of PCSK9 of Up to 96%

Financial news for MDCO dated on 2014-04-30: UPDATE: FDA Says Medicines Co.'s Cangrelor NDA Comments May Affect Labeling

Financial news for MDCO dated on 2014-04-30: The Medicines Co. Announces CRL from FDA, Requests Added Info

Financial news for MDCO dated on 2014-04-23: The Medicines Company Reports Q1 EPS of \$0.33 Which May Not Compare \$(0.07) Est; Revenue of \$177.20M Which May Not Compare \$175.57M Est

Financial news for MDCO dated on 2014-04-17: Benzinga's Top Downgrades

Financial news for MDCO dated on 2014-04-17: Leerink Swann Downgrades The Medicines Company to Market Perform, Lowers PT to \$27.00

Financial news for MDCO dated on 2014-04-03: Medicines Co Says PDUFA Date for Fibrocaps is January 31, 2015

Financial news for MDCO dated on 2014-04-02: Market Wrap For April 2: Markets On Four-Day Winning Streak

Financial news for MDCO dated on 2014-04-02: Benzinga's Top Downgrades

Financial news for MDCO dated on 2014-04-02: Piper Jaffray Downgrades The Medicines Company to Neutral, Lowers PT to \$29.00

Financial news for MDCO dated on 2014-04-01: Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke

Financial news for MDCO dated on 2014-04-01: Mid-Afternoon Market Update: Compuware Holds Onto Gains, Clearwire Remains Down

Financial news for MDCO dated on 2014-04-01: Mid-Day Market Update: Verint Shares Jump On Upbeat Results; Medicines Co. Falls

Financial news for MDCO dated on 2014-04-01: Stocks Hitting 52-Week Lows

Financial news for MDCO dated on 2014-04-01: Mid-Morning Market Update: Markets Gain; Ford March Sales Rise 3%

Financial news for MDCO dated on 2014-04-01: Morning Market Losers

Financial news for MDCO dated on 2014-04-01: Benzinga's Top #PreMarket Losers

Financial news for MDCO dated on 2014-04-01: Medicines Company Provides Update on Angiomax Patent Litigation

Financial news for MDCO dated on 2014-03-30: Medicines Company Present Pooled Analysis of 5,800 Patients in EUROMAX and HORIZONS-AMI Trials at ACC

Financial news for MDCO dated on 2014-02-19: The Medicines Company Reports Q4 EPS of \$0.26 vs \$0.11 Est; Revenue of \$185.0M vs \$182.57M Est

Financial news for MDCO dated on 2014-02-19: Earnings Scheduled For February 19, 2014

Financial news for MDCO dated on 2014-02-18: Intercept Names Sanj K. Patel and Glenn Sblendorio to Board of Directors

Financial news for MDCO dated on 2014-02-13: Mid-Afternoon Market Update: Market Rally Levels Out As Time Warner/Comcast Deal Holds The Spotlight

Financial news for MDCO dated on 2014-02-13: Mid-Day Market Update: U.S. Stocks Rise; Orbitz Shares Surge On Upbeat Results

Financial news for MDCO dated on 2014-02-13: Mid-Morning Market Update: Markets Drop; Comcast To Acquire Time Warner Cable For \$45.2B

Financial news for MDCO dated on 2014-02-13: Stocks Hitting 52-Week Lows

Financial news for MDCO dated on 2014-02-13: UPDATE: Credit Suisse Downgrades The Medicines Company Following Negative Cangrelor Panel

Financial news for MDCO dated on 2014-02-13: Benzinga's Top #PreMarket Losers

Financial news for MDCO dated on 2014-02-13: Benzinga's Top Downgrades

Financial news for MDCO dated on 2014-02-13: Jefferies Downgrades The Medicines Company to Hold, Lowers PT to \$27.00

Financial news for MDCO dated on 2014-02-13: Credit Suisse Downgrades The Medicines Company to Neutral, Lowers PT to \$35.00

Financial news for MDCO dated on 2014-02-12: Shares of The Medicines Co. Resume Trade Down ~12%

Financial news for MDCO dated on 2014-02-12: Market Wrap For February 12: Markets Take a Breather, Senate Passes Debt Limit Bill

Financial news for MDCO dated on 2014-02-12: The Medicines Co. Announces FDA CRDAC Voted to Recommend Against Approval of Cangrelor, Says NDA PDUFA Goal Date is Now Apr. 30th

Financial news for MDCO dated on 2014-02-12: Bloomberg Reporting FDA Panel Has Failed to Back Medicines Co.'s Cangrelor

Financial news for MDCO dated on 2014-02-12: UPDATE: The Medicines Co. Reminds Investors of FDA CRDAC Meeting Today, Says Proposing Cangrelor Be Indicated to Maintain P2Y12 Inhibition

Financial news for MDCO dated on 2014-02-12: Medicines Co. Proposing Cangrelor Be Indicated to Maintain P2Y12 Inhibition in Patients with Acute Coronary Syndromes, With Stents at Risk for Thrombotic Events

Financial news for MDCO dated on 2014-02-12: Medicines Co. Halted News Pending

Financial news for MDCO dated on 2014-02-10: Market Wrap For February 10: Markets Cautious Ahead Of Yellen Testimony

Financial news for MDCO dated on 2014-02-10: Mid-Afternoon Market Update: Red Robin Continues to Rally as The Medicines Company Drops

Financial news for MDCO dated on 2014-02-04: Daniel B. Ravicher Tweet: 'Post-trial briefs in \$MDCO v \$HSP Angiomax patent case completed in Dec. Decision could come any day permitting generic launch by \$HSP'

Financial news for MDCO dated on 2014-01-13: Medicines Receives QIDP Designation for Carbavance

Financial news for MDCO dated on 2014-01-10: Hearing Unconfirmed Market Chatter Medicines Co Cangrelor Injection on FDA Docket for Feb, Earlier than Expected

Financial news for MDCO dated on 2013-12-10: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

Financial news for MDCO dated on 2013-12-04: Benzinga's M&A Chatter for Wednesday

December 4, 2013

Financial news for MDCO dated on 2013-12-04: US Stock Futures Edge Higher Ahead Of ADP Report

Financial news for MDCO dated on 2013-12-04: The Medicines Company Acquires Rempex Pharmaceuticals for \$140M Plus Milestone Payments

Financial news for MDCO dated on 2013-11-07: Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates

Financial news for MDCO dated on 2013-10-23: The Medicines Company Reports Q3 EPS of \$0.47 vs \$0.21 Est; Revenue of \$174.30M vs \$173.45M Est

Financial news for MDCO dated on 2013-10-10: UPDATE: Leerink Swann Raises PT on The Medicines Company Following Analyst Meeting

Financial news for MDCO dated on 2013-10-09: The Medicines Company, Alnylam Announce Advance Development Candidate for Treatment of Hypercholesterolemia

Financial news for MDCO dated on 2013-09-25: RBC Analyst Says Hospira Has Received Tentative FDA Approval for Medicine Cos.' Angiomax

Financial news for MDCO dated on 2013-09-03: The Medicines Company's Publishes Phase III Data from Trials of IV Cangrelor

Financial news for MDCO dated on 2013-08-15: UPDATE: Bank of America Upgrades Medicines Company on Leverage

Financial news for MDCO dated on 2013-08-15: Bank of America Upgrades The Medicines Company to Buy, Raises PO to \$40.00

Financial news for MDCO dated on 2013-08-13: The Medicines Company Prices 5.785M Share Offering at \$30.25/Share

Financial news for MDCO dated on 2013-08-13: Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

Financial news for MDCO dated on 2013-08-12: The Medicines Company Announces Proposed Public Offering of 5.5 Million Shares of Common Stock

Financial news for MDCO dated on 2013-08-12: Medicines Co. Files Automatic Mixed Securities Shelf

Financial news for MDCO dated on 2013-08-05: The Medicines Company Announces Positive Phase III Trial Results for Fibrocaps; Completes ProFibrix Acquisition

Financial news for MDCO dated on 2013-08-01: Bloomberg Reporting Ligand Pharma, The Medicines Co. Have Mutually Terminated License Deal with CyDex Unit

Financial news for MDCO dated on 2013-07-24: The Medicines Company Reports Q2 EPS of \$0.30 vs \$0.34 Est; Revenue of \$172.80M vs \$168.73M Est

Financial news for MDCO dated on 2013-07-12: Market Wrap for Friday, July 12: Stocks Rise as S&P 500 Closes At New All-Time High

Financial news for MDCO dated on 2013-07-12: Mid-Afternoon Market Update: The Medicines Company Falls as Markets Remain Mixed

Financial news for MDCO dated on 2013-07-12: MDCO Shares Moving Today, Court Sides with Hospira in Claim against MDCO

Financial news for MDCO dated on 2013-07-12: Medicines Company Spikes Lower

Financial news for MDCO dated on 2013-07-02: The Medicines Company Announces Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Financial news for MDCO dated on 2013-07-01: FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor

Financial news for MDCO dated on 2013-06-24: ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)

Financial news for MDCO dated on 2013-06-21: UPDATE: Oppenheimer Assumes Medicines Company at Perform Rating on Valuation

Financial news for MDCO dated on 2013-06-20: Oppenheimer Downgrades The Medicines Company to Perform, Removes \$(aN) PT

Financial news for MDCO dated on 2013-06-05: UPDATE: Piper Jaffray Initiates The Medicines Company at Overweight on Diverse Medical Portfolio

Financial news for MDCO dated on 2013-06-05: Piper Jaffray Initiates Coverage on The Medicines Company at Overweight, Announces \$47.00 PT

Financial news for MDCO dated on 2013-06-04: RBC Believes Medicines Co. Option to Buy ProFibrix is at 'Reasonable Cost,' Maintains Outperform, \$41 Target

Financial news for MDCO dated on 2013-06-04: The Medicines Company to Acquire ProFibrix with \$10M Upfront Payment

Financial news for MDCO dated on 2013-05-21: The Medicines Co. Shares Spike Lower, Now Down 13%

Financial news for MDCO dated on 2013-05-17: Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

Financial news for MDCO dated on 2013-05-10: Stocks Hitting 52-Week Highs

Financial news for MDCO dated on 2013-04-24: The Medicines Company Reports Q1 Adj. EPS of \$0.31, GAAP Loss \$0.21/Share vs \$(0.26) Est; Revenue of \$155.80M vs \$152.66M Est

Financial news for MDCO dated on 2013-03-27: Guggenheim Securities Initiates Coverage on The Medicines Company at Buy, Announces \$39.00 PT

Financial news for MDCO dated on 2013-03-15: UPDATE: Credit Suisse Initiates The Medicines Company at Outperform on Pipeline Catalysts

Financial news for MDCO dated on 2013-03-15: Credit Suisse Initiates Coverage on The Medicines Company at Outperform, Announces \$38.00 PT

Financial news for MDCO dated on 2013-03-12: Citigroup Maintains Neutral on The Medicines Company, Raises PT to \$32.00

Financial news for MDCO dated on 2013-03-12: Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest EPS

Financial news for MDCO dated on 2013-03-11: UPDATE: Bank of America Raises PT on The Medicines Company on Higher Cangrelor Expectations

Financial news for MDCO dated on 2013-03-11: Bank of America Maintains Neutral on The Medicines Company, Raises PT to \$35.00

Financial news for MDCO dated on 2013-03-07: Unusual Options Activity: The Medicines Company March Slightly-In-The-Money March \$32.00 Puts Trade 2,763 Times Over an Open Interest of 89

Financial news for MDCO dated on 2013-02-21: Jefferies Maintains Buy on The Medicines Company, Raises PT to \$36.00

Financial news for MDCO dated on 2013-02-20: Bank of America Maintains Neutral on The Medicines Company, Raises PT to \$33.00

Financial news for MDCO dated on 2013-02-20: The Medicines Company Sees Q1 Sales \$144.0M-155.0M vs \$154.20M Est

Financial news for MDCO dated on 2013-02-20: The Medicines Company Expecting FY Sales Growth 20-22%

Financial news for MDCO dated on 2013-02-20: The Medicines Company Reports Q4 EPS of \$0.38 vs \$0.28 Est, Adj. EPS \$0.78; Revenue of \$159.50M vs \$146.09M Est

Financial news for MDCO dated on 2013-02-08: The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Financial news for MDCO dated on 2013-02-04: Jefferies Reiterates Buy Rating, \$34 PT on Partnership with Alnylam Pharmaceuticals

Financial news for MDCO dated on 2013-02-04: A Peek Into The Market Before The Trading Starts

Financial news for MDCO dated on 2013-02-04: The Medicines Company, Alnylam Announce Global Alliance

Financial news for MDCO dated on 2013-01-09: UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, Raises PT on The Medicines Company

Financial news for MDCO dated on 2013-01-09: Bank of America Maintains Neutral on The Medicines Company, Raises PO to \$30.00

Financial news for MDCO dated on 2013-01-08: Mid-Afternoon Market Update: Markets Fall Further, Isis Pharma Rallies

Financial news for MDCO dated on 2013-01-08: Mid-Day Market Update: Markets Remain Down, The Medicines Company Sees a Big Boost

Financial news for MDCO dated on 2013-01-08: The Medicines Co. Offers Results of Phase 3 Trial of Cangrelor for Treatment of Patients Undergoing PCI

Financial news for MDCO dated on 2013-01-07: The Medicines Company Completes Acquisition of Incline Therapeutics

Financial news for MDCO dated on 2013-01-02: ISI Group Initiates Coverage on The Medicines Company at Buy, Announces \$30.00 PT

Financial news for MDCO dated on 2012-12-20: UPDATE: JP Morgan Upgrades The Medicines Company to Overweight on Pipeline Outlook

Financial news for MDCO dated on 2012-12-20: Bank of America Maintains Neutral on The Medicines Company, Raises PO to \$28.00

Financial news for MDCO dated on 2012-12-20: From Earlier: JP Morgan Upgrades The Medicines Company to Overweight

Financial news for MDCO dated on 2012-12-20: JP Morgan Upgrades The Medicines Company to Overweight, Raises PT to \$32.00

Financial news for MDCO dated on 2012-12-13: Bank of America Maintains Neutral on The Medicines Company, Lowers PO to \$26.00

Financial news for MDCO dated on 2012-12-12: The Medicines Company, Bristol-Myers Squibb Announce Global Alliance for Recothrom

Financial news for MDCO dated on 2012-12-12: Cadence Pharmaceuticals, Medicines Company Resume Trading

Financial news for MDCO dated on 2012-12-12: PREVIEW: Cadence Pharmaceuticals, Medicines Company to Resume Trading at 7:35 AM

Financial news for MDCO dated on 2012-12-12: Cadence Pharmaceuticals Terminates Option Agreement to Acquire Incline Therapeutics

Financial news for MDCO dated on 2012-12-12: Medicines Company to Acquire Incline Therapeutics

Financial news for MDCO dated on 2012-11-20: UPDATE: Oppenheimer Initiates The Medicines Company at Outperform on Pipeline Value

Financial news for MDCO dated on 2012-11-19: Oppenheimer Initiates Coverage on Medicines at Outperform, Announces PT of \$35

Financial news for MDCO dated on 2012-11-19: SAC Capital Discloses 5% Passive Stake in Medicines Co.

Financial news for MDCO dated on 2012-10-26: UPDATE: Citigroup Initiates Coverage on The Medicines Company with Neutral Rating, \$27 PT

Financial news for MDCO dated on 2012-10-25: Citigroup Initiates Coverage on Medicines at Neutral, Announces PT of \$27

Financial news for MDCO dated on 2012-10-24: Bank of America Maintains Medicines at Neutral, Lowers PO from \$29 to \$28

Financial news for MDCO dated on 2012-10-24: Medicines Reports Q3 EPS \$0.40 vs \$0.21 Est; Revenues \$136.8M vs \$136.46M Est

Financial news for MDCO dated on 2012-10-24: Medicines Reports Q3 EPS \$0.40 May Not Compare to \$0.21 Est; Revenues \$136.8M vs \$136.46M Est

Financial news for MDCO dated on 2012-10-18: Options Alert - Medicines Co.

Financial news for MDCO dated on 2012-10-16: UPDATE: Jefferies Upgrades The Medicines Company to Buy on Attractive Risk/Reward

Financial news for MDCO dated on 2012-10-16: Benzinga's Top Upgrades

Financial news for MDCO dated on 2012-10-16: Jefferies & Company Upgrades Medicines from Hold to Buy, Raises PT from \$24 to \$34

Financial news for MDCO dated on 2012-10-04: The Medicines Company Stops Phase 2b Trial of MDCO-2010

Financial news for MDCO dated on 2012-09-10: Annovation Biopharma Raises \$8M to Develop Novel Anesthetics

Financial news for MDCO dated on 2012-09-05: Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash

Financial news for MDCO dated on 2012-08-22: UPDATE: Bank of America Initiates Neutral, \$29 PO on The Medicines Company; Pipeline Uncertain

Financial news for MDCO dated on 2012-08-22: Bank of America Initiates Coverage on Medicines at Neutral, Announces PO of \$29

Financial news for MDCO dated on 2012-07-25: Medicines Reports Q2 EPS \$0.25 vs \$0.17 Est; Revenues \$135.7M vs \$131.78M Est

Financial news for MDCO dated on 2012-07-02: The Medicines Company Expects Cangrelor Phase 3 Trial Enrollment Completion in 2012

Financial news for MDCO dated on 2012-06-06: The Medicines Company Prices \$225 Million of Convertible Notes

Financial news for MDCO dated on 2012-06-05: A Peek Into The Market Before The Trading Starts

Financial news for MDCO dated on 2012-06-05: The Medicines Company Announces Intention to Offer \$200 Million of Convertible Notes

Financial news for MDCO dated on 2012-04-25: AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease

Financial news for MDCO dated on 2012-04-25: Medicines Reports Q1 EPS \$0.27 May Not Compare vs \$0.11 Est; Revenues \$126.6M vs \$123.69M Est

Financial news for MDCO dated on 2012-03-26: Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients

Financial news for MDCO dated on 2012-03-06: Medicines Company Spiking Higher

Financial news for MDCO dated on 2012-02-23: UPDATE: Auriga Raises Price Target on the Medicines Company to \$25

Financial news for MDCO dated on 2012-02-23: Auriga Maintains Medicines at Buy, Raises PT from \$23.5 to \$25

Financial news for MDCO dated on 2012-02-22: Medicines Reports Q4 EPS \$0.52 vs \$0.24 Est; Revenues \$132.2M vs \$124.99M Est

Financial news for MDCO dated on 2012-02-22: Medicines Reports Q4 EPS \$0.52 vs \$0.24 Est; Revenues \$132.2M vs \$124.99M Est

Financial news for MDCO dated on 2012-02-13: Blue Dolphin Energy Spokesperson Says No News to Account for Today's Huge Price Rise

Financial news for MDCO dated on 2012-01-31: Medicines Co Trading 1.1% Higher on Heavy Volume; Currently at \$20.07

Financial news for MDCO dated on 2012-01-31: Potential Trades This Week: Looking For Consolidation

Financial news for MDCO dated on 2012-01-29: Weekly Traders Homework: Frustrated Bears

Financial news for MDCO dated on 2012-01-23: The Medicines Company Settles Angiomax Patent Litigations With App Pharmaceuticals

Financial news for MDCO dated on 2012-01-09: Notable Put Options Activity in The Medicines Company

Financial news for MDCO dated on 2011-11-14: The Medicines Company's MDCO-216 Demonstrates Capacity to Clear Cholesterol From Cells in Preclinical Model

Financial news for MDCO dated on 2011-11-02: Are Upcoming Study Results Spurring



Insider Buying at Ligand Pharmaceuticals?

Financial news for MDCO dated on 2011-10-04: Monday's NASDAQ Winners: Intricon, Pharmaceutical Product Development, The Medicines Company, Ener1

Financial news for MDCO dated on 2011-10-04: UPDATE: Citi Raises PT on The Medicines Company to \$27

Financial news for MDCO dated on 2011-10-03: The Medicines Company Launches New Formulation of Cleviprex Injectable Emulsion

Financial news for MDCO dated on 2011-10-03: Citigroup Raises PT on The Medicines Company to \$24

Financial news for MDCO dated on 2011-10-03: Pre-Market Movers; The Medicines Company up 10%

Financial news for MDCO dated on 2011-10-03: The Medicines Company Settles Angiomax Patent Litigations With Teva

Financial news for MDCO dated on 2011-09-12: The Medicines Company Launches 50mL Ready-to-Use Formulation of Argatroban Injection

Financial news for MDCO dated on 2011-07-27: Medicines Co Reports Q2 EPS of \$0.24 vs. \$0.20 Est; Revenues \$119.6M vs. \$117.66M Est

Financial news for MDCO dated on 2011-06-03: Ligand and Medicines Company Agree to Worldwide License for Proprietary Captisol(r)-Enabled Intravenous Formulation of Clopidogrel

Financial news for MDCO dated on 2011-05-31: Benzinga's Volume Movers

Financial news for MDCO dated on 2011-05-31: NASDAQ Stocks Hitting 52-Week Highs

Financial news for MDCO dated on 2011-05-31: Benzinga's Top Pre-Market NASDAQ Gainers

Financial news for MDCO dated on 2011-04-27: The Medicines Company Reports EPS of \$0.45 vs. \$0.40 Estimate; Revenues \$112.1M vs. \$109.69M Estimate (MDCO)

Financial news for MDCO dated on 2011-04-25: Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates (CHBT, MDCO, PTX, SCR)

Financial news for MDCO dated on 2011-02-18: Stocks on the Move:(MDCO) New High

Financial news for MDCO dated on 2010-12-09: Positive on The Medicines Co. - Analyst Blog

Financial news for MDCO dated on 2010-12-09: Positive on The Medicines Co. - Analyst Blog

Financial news for MDCO dated on 2010-11-30: Trial Design Set for MDCO Candidate - Analyst Blog

Financial news for MDCO dated on 2010-11-30: Trial Design Set for MDCO Candidate - Analyst Blog

Financial news for MDCO dated on 2010-10-28: Lower Costs Drive MDCO - Analyst Blog

Financial news for MDCO dated on 2010-10-27: The Medicines Company Reports Third Quarter EPS of \$.43

Financial news for MDCO dated on 2010-10-07: Good News for MDCO - Analyst Blog

Financial news for MDCO dated on 2010-10-07: Stock Downgrades: (TTES, CTL, MDCO, IRM, COST)

Financial news for MDCO dated on 2010-09-16: Unconfirmed Chatter that Merck & Co. Inc. (MRK) will buy Medicines Co. (MDCO) at \$23.00 a share

Financial news for MDCO dated on 2010-08-12: Shares of Medicines Co Moved Higher Today (MDCO)

Financial news for MDCO dated on 2010-08-04: Benzinga's Top Pre-Market NASDAQ Losers (MDCO, WPPGY, RIMM, BIDU)

Financial news for MDCO dated on 2010-08-03: Shares Of The Medicines Company Exploding After Court Ruling (MDCO)

Financial news for MDCO dated on 2010-06-04: Keep Tight Risk and Capital Management

06-04-2010

Financial news for MDCO dated on 2010-06-02: Bonds May Be Signaling... 05-28-2010

Financial news for MDCO dated on 2010-05-28: Calls Sold on The Medicines Co. (MDCO)

Financial news for MDCO dated on 2010-04-19: Top 5 Stocks In The Healthcare Sector With Lowest PEG (PDLI, PRX, MDCO, UTHR, CPIX)

Financial news for MDCO dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for MDCO dated on 2010-03-18: Movers And Shakers Of March 17 (AIB, ABII, BLK, LSI, MDCO, PLCM, VHC, TIN)

Financial news for MDCO dated on 2010-03-17: Benzinga's Top Pre-Market Gainers (PLCM, ADSK, MDCO, GNVC)

Financial news for MDCO dated on 2010-01-12: Medicines Cuts Jobs (MDCO)

Financial news for MDCO dated on 2009-12-23: Medicines Co. Buys Heart Drug from Pfizer: BioBuzz (MDCO, PFE)

Financial news for MDCO dated on 2009-09-02: The Medicines Company (MDCO) Secured Patent for Angiomax

Financial news for MDCO dated on 2009-08-14: The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 5635

Financial news for MDCO dated on 2009-08-10: The Medicines Company Responds to Incorrect News Reports